A double-blind, placebo-controlled trial of fluvoxamine versus imipramine in outpatients with major depression.
The authors employed a double-blind, placebo-controlled design to investigate the effectiveness of fluvoxamine versus imipramine in 54 outpatients with moderate major depression. Fluvoxamine proved superior to placebo but not to imipramine on the Hamilton Rating Scale for Depression and the Montgomery and Asberg Depression Rating Scale. Nausea and hyperarousal were the most common side effects in the fluvoxamine-treated patients.
March
J S
JS
Department of Psychiatry, University of Wisconsin Hospital, Madison 53792.
Kobak
K A
KA
Jefferson
J W
JW
Mazza
J
J
Greist
J H
JH
D000293:Adolescent; D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D000928:Antidepressive Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D016666:Fluvoxamine; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use*; D008875:Middle Aged; D010091:Oximes / Q000627:therapeutic use*; D010919:Placebos
D000928:Antidepressive Agents; D010091:Oximes; D010919:Placebos; D016666:Fluvoxamine; D007099:Imipramine